Citations

Clear

1446 citation(s) found for "Howard, F".

Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease
Shirzadi, Zahra , Schultz, Stephanie A. , Yau, Wai‐Ying Wendy , Fitzpatrick, Colleen , Levin, Raina, Kantarci, Kejal , Preboske, Gregory M., Jack, Clifford R. , Farlow, Martin R. , Hassenstab, Jason , Morris, John C. , Xiong, Chengjie , Levey, Allan I. , Gordon, Brian A. , Salloway, Stephen , Perrin, Richard J. , Xiong, Chengjie , Fox, Nick C. , Goate, Alison , Day, Gregory S. , Chui, Helena C., Berman, Sarah , Mori, Hiroshi , Ruthirakuhan, Myuri , Wu, Che‐Yuan , Sohrabi, Hamid R. , Martins, Ralph N. , Johnson, Keith A. , Greenberg, Steven M. , Chhatwal, Jasmeer P. , Initiative, Dominantly Inherited Alzheimer Network and the Alzheimer’s Disease Neuroimaging, Weiner, Michael W. , Aisen, Paul, Petersen, Ronald , Jack, Clifford R., Jagust, William J. , Trojanowki, John Q., Morris, John C., Shaw, Leslie M. , Khachaturian, Zaven S., Carrillo, Maria, Potter, William Z., Bernard, Marie , Jackson, Jonathan , Masliah, Eliezer , Masterman, Donna, Okonkwo, Ozioma C. , Ryan, Laurie, Silverberg, Nina, Fleisher, Adam , Sacrey, Diana Truran, Fockler, Juliet , Conti, Cat, Jin, Chengshi , Nosheny, Rachel L. , Ashford, Miriam T. , Flenniken, Derek , Kormos, Adrienne, Montine, Tom, Raman, Rema , Jiménez, Gustavo , Gessert, Devon, Salazar, Jennifer, Zimmerman, Caileigh, Cabrera, Yuliana, Walter, Sarah , Miller, Garrett, Coker, Godfrey, Clanton, Taylor, Hergesheimer, Lindsey, Adegoke, Olusegun, Mahboubi, Payam, Moore, Shelley, Pizzola, Jeremy, Shaffer, Elizabeth , Sloan, Brittany, Forghanian-Arani, Arvin, Borowski, Bret, Ward, Chad, Gunter, Jeff, Jahanshad, Neda , DeCarli, Charles, Knaack, Alexander , Chen, Stephanie Rossi, Choe, Mark, Crawford, Karen , Reiman, Eric M. , Mathis, Chet, Landau, Susan, Cairns, Nigel J., Householder, Erin, Franklin, Erin , Bernhardt, Haley, Taylor‐Reinwald, Lisa, Korecka, Magdalena , Figurski, Michael, Neu, Scott, Apostolova, Liana G. , Foroud, Tatiana M., Faber, Kelley, Wilmes, Kristi, Thal, Leon J., Lind, Betty, Crissey, Rachel, Carter, Raina, Dolen, Sara, Schneider, Lon S. , Pawluczyk, Sonia, Becerra, Mauricio, Teodoro, Liberty, Dagerman, Karen, Spann, Bryan M., Brewer, James B., Vanderswag, Helen, Ziolkowski, Jaimie, Heidebrink, Judith L. , Zbizek-Nulph, Lisa, Mason, Sara S., Albers, Colleen S., Johnson, Kris , Villaneuva-Meyer, Javier, Pavlik, Valory , Pacini, Nathaniel, Lamb, Ashley, Kass, Joseph S. , Doody, Rachelle S., Shibley, Victoria, Chowdhury, Munir , Rountree, Susan, Dang, Mimi, Mintz, Akiva , Winkfield, David, Carroll, Maria , Stobbs-Cucchi, Georgia , Oliver, Angela , Creech, Mary L., Mintun, Mark A., Schneider, Stacy, Geldmacher, David , Love, Marissa Natelson , Griffith, Randall, Clark, David, Brockington, John, Marson, Daniel , Grossman, Hillel, Goldstein, Martin , Mitsis, Effie, Samuels, Patricia, Duara, Ranjan , Greig‐Custo, Maria T., Rodriguez, Rosemarie, Albert, Marilyn, Onyike, Chiadi, Farrington, Leonie, Rudow, Scott, Brichko, Rottislav, Kielb, Stephanie , Smith, Amanda , Raj, Balebail Ashok, Fargher, Kristin, Shulman, Melanie , Faustin, Arline , Rao, Julia, Castro, Karen M. , Ulysse, Anaztasia, Chen, Shannon, Sheikh, Mohammed O., Singleton-Garvin, Jamika, Doraiswamy, P. Murali , Petrella, Jeffrey R. , James, Olga, Borges‐Neto, Salvador , Karlawish, Jason , Vaishnavi, Sanjeev , Clark, Christopher M. , Arnold, Steven E. , Smith, Charles D. , Khouli, Riham El , Raslau, Flavius D., Oakley, MaryAnn, Simpson, Donna M., Martin, Kim, Kowalski, Nancy, Keltz, Melanie, Goldstein, Bonnie S., Makino, Kelly M., Ismail, M. Saleem , Brand, Connie, Thai, Gaby , Pierce, Aimee, Witbracht, Megan , Mathews, Dana, Quiceno, Mary , Hajjar, Ihab , Cellar, Janet S., Swerdlow, Russell H. , Kremen, Sarah , Tingus, Kathleen, Lu, Po H. , Bartzokis, George, Woo, Ellen, Graff‐Radford, Neill R. , Parfitt, Francine, Poki-Walker, Kim, Hake, Ann Marie , Matthews, Brandy R., Herring, Scott, Dyck, Christopher H. van , Mecca, Adam P. , Good, Susan P., MacAvoy, Martha G., Carson, Richard E. , Varma, Pradeep, Chertkow, Howard , Vaitekunis, Susan, Hosein, Chris, Mudge, Benita, Assaly, Michele, Rachinsky, Irina, Kertesz, Andrew, Drost, Dick, Rogers, John, Grant, Ian , Muse, Brittanie, Rogalskı, Emily , Robson, Jordan, Mesulam, M.‐Marsel, Kerwin, Diana , Wu, Chuang‐Kuo, Johnson, Nancy E., Lipowski, Kristine, Weıntraub, Sandra , Bonakdarpour, Borna , Hernando, Raymundo, Sarrael, Antero, Rosen, Howard J., Johnson, Kathleen, Reynolds, Brigid, Poe, Jessica, Sperling, Reisa A., Marshall, Gad A. , Yesavage, Jerome A. , Taylor, Joy L. , Chao, Steven, Coleman, Jaila, White, Jessica D. , Lane, Barton , Rosen, Allyson , Tinklenberg, Jared, Belden, Christine M. , Clark, Kelly, Zamrini, Edward , Sabbagh, Marwan, Kowall, Neil W. , Budson, Andrew E. , Ntekim, Oyonumo, Wolday, Saba, Khan, Javed , Nwulia, Evaristus , Nadarajah, Sheeba , Lerner, Alan J. , Ogrocki, Paula, Tatsuoka, Curtis , Fatica, Parianne, Olichney, John , Bates, Vernice, Capote, Horacio, Rainka, Michelle, Borrie, Michael, Lee, T‐Y, Asthana, Sanjay , Carlsson, Cynthia M., Perrin, Allison, Burke, Anna , Kataki, Maria , Hart, David , Zimmerman, Earl A. , Celmins, Dzintra, Smith, Karen Ekstam, Shim, Hyungsub , Nam, Ki Won , Schtulz, Susan K., Williamson, Jeff D. , Craft, Suzanne , Cleveland, Jo, Ott, Brian R. , Drake, Jonathan, Tremont, Geoffrey , Daiello, Lori A. , Ritter, Aaron, Bernick, Charles , Munic, Donna, O’Connell, Abigail, Mintzer, Jacobo , Wiliams, Arthur, Masdeu, Joseph C. , Shi, Jiong , Garcia, Angelica, Newhouse, Paul , Salloway, Steven, Malloy, Paul, Correia, Stephen , Kittur, Smita, Blank, Karen, Anderson, Karen, Flashman, Laura A. , Seltzer, Marc, Hynes, Mary L. , Santulli, Robert B. , Relkin, Norman , Chiang, Gloria, Lee, Athena, Lin, Michael, Ravdin, Lisa , Sood, Ajay, Blanchard, Kimberly S., Fleischman, Debra , Varon, Daniel, Greig, Maria T., Martin, Kimberly S., Reist, Christopher , Sadowsky, Carl, Villena, Teresa, Rosen, Howard, Peskind, Elaine R. , Li, Gail, Vöglein, Jonathan , Méndez, Patricio Chrem, Ikonomović, Snežana, Nadkarni, Neelesh K. , Ramírez, Laura, Leon, Yudy Milena, Ramos, Cláudia , Alzate, Diana, Baena, Ana , Londono, Natalia, Laske, Christoph , Kuder-Buletta, Elke, Gräber‐Sultan, Susanne, Preische, Oliver, Hofmann, Anna, Ishii, Kenji , Senda, Michio , Riddle, Meghan C., Menard, William, Bodge, Courtney, Surti, Mustafa, Sanchez-Gonzalez, VJ, Orozco-Barajas, Maribel, Esposito, Bianca, Fernanadez, Victoria, Jerome, Gina, Herries, Elizabeth, Seyfried, Nicholas T. , Bechara, Jacob , Chen, Allison , Hantler, Nancy, Hornbeck, Russ C. , Jarman, Steve, Keefe, Sarah , Koudelis, Deborah, Massoumzadeh, Parinaz , Nicklaus, Joyce , Pulizos, Christine, Mishall, Sheetal, Sabaredzovic, Edita, Deng, Emily , Candela, Madison, Smith, Hunter , Scott, Jalen , Gremminger, Emily, Ma, Yinjiao , Bui, Ryan , Lu, Ruijin , Daniels, Alisha , Courtney, Laura, Supnet, Charlene , Xu, Jinbin , Ringman, John M. , Barthélemy, Nicolas R. , Jack, Clifford R , Gordon, Brian A , Kantarci, Kejal , Day, Gregory S , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Supnet-Bell, Charlene , Berman, Sarah , Levey, Allan I , Kremen, Sarah , Joseph‐Mathurin, Nelly , Jucker, Mathias , Xiong, Chengjie , Karch, Celeste M. , Schofield, Peter R. , McDade, Eric , Cruchaga, Carlos , Allegri, Ricardo , Koeppe, Robert A. , Chui, Helena C. , Sánchez‐Valle, Raquel , Lee, Jae‐Hong , Rosa-Neto, Pedro , Swardfager, Walter , Benzinger, Tammie L.S. , Bateman, Randall J. , Sperling, Reisa Anne , Schultz, Aaron P. , Initiative, Dominantly Inherited Alzheimer Network and the Alzheimer’s Disease Neuroimaging, Jack, Clifford R., Toga, Arthur W. , Beckett, Laurel , Green, Robert C. , Saykin, Andrew J. , Morris, John C., Barnes, Lisa L. , González, Hector, Ho, Carole , Hsiao, John , Veitch, Dallas P. , Neuhaus, John M , Rafii, Michael S. , Donohue, Michael , Smith, Stephanie R. , Harvey, Danielle , Arani, Arvin , Schwarz, Christopher G. , Jones, David T. , Senjem, Matthew L. , Vemuri, Prashanthi , Reid, Robert I. , Malone, Ian B. , Thompson, Paul M. , Thomopoulos, Sophia I. , Nir, Talia M. , Fletcher, Evan M. , Tosun, Duygu , Yushkevich, Paul A. , Das, Sandhitsu R. , Chen, Kewei , Mathis, Chet, Nho, Kwangsik T. , Risacher, Shannon L. , Shen, Li , Nudelman, Kelly , Silbert, Lisa C. , Kaye, Jeffrey , Carter, Raina, Quinn, Joseph F. , Lord, Joanne L. , Knopman, David S. , Stern, Yaakov , Honig, Lawrence S. , Ances, Beau M. , Goldstein, Martin A., Greenberg, Jonathan, Shah, Raj C. , Lamar, Melissa , Duara, Ranjan , Sadowski, Martin , Wısnıewskı, Thomas , Wong, Terence Z. , Wolk, David A. , Jicha, Gregory A. , López, Oscar L. , Porsteinsson, Anton P. , Yanez, Beatriz, Sosa, Elizabeth M. , Kelley, Brendan , Nguyen, Trung Dung , Womack, Kyle , Lah, James J. , Burns, Jeffrey M. , Brooks, William Miles , Silverman, Daniel H.S. , Teng, Edmond , Brosch, Jared R. , Black, Sandra E. , Stefanovic, Bojana , Heyn, Chris , Hsiung, Ging‐Yuek Robin , Kim, Ellen , Sossi, Vesna , Feldman, Howard , Finger, Elizabeth C. , Pasternak, Stephen , Miller, Bruce L. , Perry, David C. , Turner, Raymond Scott , MCCann, Kelly, Sperling, Reisa A., Atri, Alireza , Killiany, Ronald , Stern, Robert A. , Mez, Jesse , Obisesan, Thomas O. , Maillard, Pauline , Carmichael, Owen , Bartha, Robert , Johnson, Sterling C. , Carlsson, Cynthia M. , Scharre, Douglas W. , Tarawneh, Rawan M. , Miller, Del D. , Ponto, Laura L. Boles , Koleva, Hristina , Yang, Mia , Sink, Kaycee M. , Masdeu, Joseph C , Potkin, Steven G. , Salloway, Steve , Pearlson, Godfrey D. , Sood, Ajay, Arfanakis, Konstantinos , Varón, Daniel , Martínez, Walter Fabián , Petrie, Eric C. , Noble, James M. , Surace, Ezequiel , Lopera, Francisco Javier , Aguillon, David , Londono, Natalia, Moreno, Sonia, Ikeuchi, Takeshi , Kasuga, Kensaku , Niimi, Yoshiki , Cash, David M. , Roh, Jee Hoon , Takada, Leonel Tadao , Renton, Alan , Marsh, Jacob A. , Llibre‐Guerra, Jorge J. , Johnson, Erik C. B. , Brooks, William S. , Chen, Charles , Flores, Shaney , McCullough, Austin , McKay, Nicole S. , Wáng, Qīng , Candela, Madison, Hobbs, Diana A. , Wang, Peter , Xu, Xiong, Li, Yan , Sosa, Ana Luisa , Smith, Jennifer A.

Mayo Clinic

JAMA Neurology | October 16, 2023 | Volume: 80 | Issue: 12 | Pages: 1353

10.1001/jamaneurol.2023.3618 | PMID 37843849 Get It

ImportanceIncreased white matter hyperintensity (WMH) volume is a common magnetic resonance imaging (MRI) finding in both autosomal dominant Alzheimer disease (ADAD) and late-onset Alzheimer disease (LOAD), but it remains unclear whether increased WMH along the AD continuum is reflective of AD-intrinsic processes or secondary to elevated systemic vascular risk factors.ObjectiveTo estimate the associations of neurodegeneration and parenchymal and vessel amyloidosis with WMH accumulation and investigate whether systemic vascular risk is associated with WMH beyond these AD-intrinsic processes.Design, Setting, and ParticipantsThis cohort study used data from 3 longitudinal cohort studies conducted in tertiary and community-based medical centers—the Dominantly Inherited Alzheimer Network (DIAN; February 2010 to March 2020), the Alzheimer’s Disease Neuroimaging Initiative (ADNI; July 2007 to September 2021), and the Harvard Aging Brain Study (HABS; September 2010 to December 2019).Main Outcome and MeasuresThe main outcomes were the independent associations of neurodegeneration (decreases in gray matter volume), parenchymal amyloidosis (assessed by amyloid positron emission tomography), and vessel amyloidosis (evidenced by cerebral microbleeds [CMBs]) with cross-sectional and longitudinal WMH.ResultsData from 3960 MRI sessions among 1141 participants were included: 252 pathogenic variant carriers from DIAN (mean [SD] age, 38.4 [11.2] years; 137 [54%] female), 571 older adults from ADNI (mean [SD] age, 72.8 [7.3] years; 274 [48%] female), and 318 older adults from HABS (mean [SD] age, 72.4 [7.6] years; 194 [61%] female). Longitudinal increases in WMH volume were greater in individuals with CMBs compared with those without (DIAN: t = 3.2 [P = .001]; ADNI: t = 2.7 [P = .008]), associated with longitudinal decreases in gray matter volume (DIAN: t = −3.1 [P = .002]; ADNI: t = −5.6 [P < .001]; HABS: t = −2.2 [P = .03]), greater in older individuals (DIAN: t = 6.8 [P < .001]; ADNI: t = 9.1 [P < .001]; HABS: t = 5.4 [P < .001]), and not associated with systemic vascular risk (DIAN: t = 0.7 [P = .40]; ADNI: t = 0.6 [P = .50]; HABS: t = 1.8 [P = .06]) in individuals with ADAD and LOAD after accounting for age, gray matter volume, CMB presence, and amyloid burden. In older adults without CMBs at baseline, greater WMH volume was associated with CMB development during longitudinal follow-up (Cox proportional hazards regression model hazard ratio, 2.63; 95% CI, 1.72-4.03; P < .001).Conclusions and RelevanceThe findings suggest that increased WMH volume in AD is associated with neurodegeneration and parenchymal and vessel amyloidosis but not with elevated systemic vascular risk. Additionally, increased WMH volume may represent an early sign of vessel amyloidosis preceding the emergence of CMBs.
The Future Ain’t What It Used to Be…Out With the Old…In With the Better: Antibacterial Resistance Leadership Group Innovations
Patel, Robin , Hamasaki, Toshimitsu , Howard‐Anderson, Jessica , Kinamon, Tori, King, H. A. , Cross, H. R. , Chambers, Henry F. , Fowler, Vance G. , Boucher, Helen W., Group, for the Antibacterial Resistance Leadership, Schooley, Robert T. , Banerjee, Ritu , Souli, Maria , Sund, Zoë, Evans, Beth , Booth, Grant, Estes, Leslie, Greenwood‐Quaintance, Kerryl E. , Parmar, Krupa , Schwager, Nyssa, Wickward, Cathy, Geres, Holly, Dai, Weixiao , He, Yijie, Doernberg, Sarah B. , Satlin, Michael J. , Rouphael, Nadine , Baum, Keri, Raza, Praneeta , Komarow, Lauren , Hopkins, D. E., Zhang, Shanshan , Patel, Robin , Evans, Scott R , Evans, Scott , King, Heather A, Collyar, Deborah , Cross, Heather R, Fowler, Vance G. , Group, for the Antibacterial Resistance Leadership, Tamma, Pranita D. , Evans, Beth, Cunningham, Scott A. , Tillekeratne, L. Gayani , Dodd, Andrew, Hopkins, Deborah, Li, Yixuan , Tsalik, Ephraim L. , Holland, Thomas L

Mayo Clinic

Clinical Infectious Diseases | October 16, 2023 | Volume: 77 | Issue: Supplement_4 | Pages: S321-S330

10.1093/cid/ciad538 | PMID 37843122 Get It

Abstract Clinical research networks conduct important studies that would not otherwise be performed by other entities. In the case of the Antibacterial Resistance Leadership Group (ARLG), such studies include diagnostic studies using master protocols, controlled phage intervention trials, and studies that evaluate treatment strategies or dynamic interventions, such as sequences of empiric and definitive therapies. However, the value of a clinical research network lies not only in the results from these important studies but in the creation of new approaches derived from collaborative thinking, carefully examining and defining the most important research questions for clinical practice, recognizing and addressing common but suboptimal approaches, and anticipating that the standard approaches of today may be insufficient for tomorrow. This results in the development and implementation of new methodologies and tools for the design, conduct, analyses, and reporting of research studies. These new methodologies directly impact the studies conducted within the network and have a broad and long-lasting impact on the field, enhancing the scientific value and efficiency of generations of research studies. This article describes innovations from the ARLG in diagnostic studies, observational studies, and clinical trials evaluating interventions for the prevention and treatment of antibiotic-resistant bacterial infections.
The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions
Chambers, Henry F. , Cross, H. R. , Souli, Maria , Patel, Robin , Fowler, Vance G. , Group, for the Antibacterial Resistance Leadership, Deckard, Nancie , Schuler, Carl, Bunn, Ivra, Zaharoff, Smitha, Sharma, Shrabani, Wickward, Cathy, Waller, Jason, Wilson, Holly, Baum, Keri, Komarow, Lauren , Evans, Beth , Hopkins, D. E., Ge, Lizhao , Giri, Abhigya, Dai, Weixiao , Diao, Guoqing , Fidler, Tamara, Shao, Wanying, Schwager, Nyssa, Mau, Donald, Satlin, Michael J. , Schooley, Robert T. , Sund, Zoë, Booth, Grant, Estes, Leslie, Greenwood‐Quaintance, Kerryl E. , Parmar, Krupa , Doernberg, Sarah B. , Raza, Praneeta , Zeng, Lijuan , Banerjee, Ritu , Abbenante, Erin, Mocka, Elizabeth, King, H. A. , Kinamon, Tori, Boucher, Helen W., Geres, Holly, He, Yijie, Mehigan, Maureen, Ghazaryan, Varduhi , Raterman, Erica L., Samuel, Tamika, Lee, Marina S. , Fowler, Vance G. , Patel, Robin , Evans, Scott R , Cross, Heather R, Evans, Scott , Group, for the Antibacterial Resistance Leadership, Lodise, Thomas P. , Schuler, Carl, Holland, Thomas L , Turner, Nicholas , Wilson, Holly, van Duin, David , Wang, Minggui, Evans, Beth, Hopkins, Deborah, Bonomo, Robert A. , Li, Yixuan , Tamma, Pranita D. , Hamasaki, Toshimitsu , Cunningham, Scott A. , Dodd, Andrew, Tsalik, Ephraim L. , Tillekeratne, L. Gayani , King, Heather, Kinamon, Tori, Howard‐Anderson, Jessica , Nayak, Seema , Samuel, Tamika

Mayo Clinic

Clinical Infectious Diseases | October 16, 2023 | Volume: 77 | Issue: Supplement_4 | Pages: S279-S287

10.1093/cid/ciad475 | PMID 37843121 Get It

AbstractIn this overview, we describe important contributions from the Antibacterial Resistance Leadership Group (ARLG) to patient care, clinical trials design, and mentorship while outlining future priorities. The ARLG research agenda is focused on 3 key areas: gram-positive infections, gram-negative infections, and diagnostics. The ARLG has developed an innovative approach to clinical trials design, the desirability of outcome ranking (DOOR), which uses an ordinal measure of global outcome to assess both benefits and harms. DOOR was initially applied to observational studies to determine optimal dosing of vancomycin for methicillin-resistant Staphylcococcus aureus bacteremia and the efficacy of ceftazidime-avibactam versus colistin for the treatment of carbapenem-resistant Enterobacterales infection. DOOR is being successfully applied to the analysis of interventional trials and, in collaboration with the US Food and Drug Administration (FDA), for use in registrational trials. In the area of diagnostics, the ARLG developed Master Protocol for Evaluating Multiple Infection Diagnostics (MASTERMIND), an innovative design that allows simultaneous testing of multiple diagnostic platforms in a single study. This approach will be used to compare molecular assays for the identification of fluoroquinolone-resistant Neisseria gonorrhoeae (MASTER GC) and to compare rapid diagnostic tests for bloodstream infections. The ARLG has initiated a first-in-kind randomized, double-blind, placebo-controlled trial in participants with cystic fibrosis who are chronically colonized with Pseudomonas aeruginosa to assess the pharmacokinetics and antimicrobial activity of bacteriophage therapy. Finally, an engaged and highly trained workforce is critical for continued and future success against antimicrobial drug resistance. Thus, the ARLG has developed a robust mentoring program targeted to each stage of research training to attract and retain investigators in the field of antimicrobial resistance research.
Magnetic Resonance Imaging of Iron Metabolism with T2* Mapping Predicts an Enhanced Clinical Response to Pharmacologic Ascorbate in Patients with GBM
Petronek, Michael S. , Monga, Varun , Bodeker, Kellie L. , Kwofie, Michael , Lee, Chu‐Yu , Stolwijk, Jeffrey M. , Zaher, Amira , Wagner, Brett A. , Smith, Mark C. , Vollstedt, Sandy , Brown, Heather , Chandler, Meghan L. , Lorack, Amanda C. , Wulfekuhle, Jared S. , Flynn, Ryan T. , Jones, Karra A. , Magnotta, Vincent A. , Mapuskar, Kranti A , Stolwijk, Jeffrey M , Zaher, Amira , Wagner, Brett A , Smith, Mark C , Vollstedt, Sandy , Brown, Heather , Chandler, Meghan L , Lorack, Amanda C , Wulfekuhle, Jared S , Sarkaria, Jann N , Flynn, Ryan T , Greenlee, Jeremy D W , Howard, Matthew A , Smith, Brian J , Jones, Karra A , Buettner, Garry R , Cullen, Joseph J , St-Aubin, Joel , Buatti, John M , Magnotta, Vincent A , Spitz, Douglas R , Allen, Bryan G , Monga, Varun , Mapuskar, Kranti A. , Sarkaria, Jann N. , Greenlee, Jeremy D.W. , Howard, Matthew A. , Buettner, Garry R. , Buatti, John M. , Spitz, Douglas R.

Mayo Clinic

Clinical Cancer Research | September 29, 2023 | Volume: 30 | Issue: 2 | Pages: 283-293

10.1158/1078-0432.ccr-22-3952 | PMID 37773633 Get It

Abstract Purpose: Pharmacologic ascorbate (P-AscH−) is hypothesized to be an iron (Fe)-dependent tumor-specific adjuvant to chemoradiation in treating glioblastoma (GBM). This study determined the efficacy of combining P-AscH− with radiation and temozolomide in a phase II clinical trial while simultaneously investigating a mechanism-based, noninvasive biomarker in T2* mapping to predict GBM response to P-AscH− in humans. Patients and Methods: The single-arm phase II clinical trial (NCT02344355) enrolled 55 subjects, with analysis performed 12 months following the completion of treatment. Overall survival (OS) and progression-free survival (PFS) were estimated with the Kaplan–Meier method and compared across patient subgroups with log-rank tests. Forty-nine of 55 subjects were evaluated using T2*-based MRI to assess its utility as an Fe-dependent biomarker. Results: Median OS was estimated to be 19.6 months [90% confidence interval (CI), 15.7–26.5 months], a statistically significant increase compared with historic control patients (14.6 months). Subjects with initial T2* relaxation < 50 ms were associated with a significant increase in PFS compared with T2*-high subjects (11.2 months vs. 5.7 months, P < 0.05) and a trend toward increased OS (26.5 months vs. 17.5 months). These results were validated in preclinical in vitro and in vivo model systems. Conclusions: P-AscH− combined with temozolomide and radiotherapy has the potential to significantly enhance GBM survival. T2*-based MRI assessment of tumor iron content is a prognostic biomarker for GBM clinical outcomes. See related commentary by Nabavizadeh and Bagley, p. 255
Long-term evaluation of clinical success and safety of omadacycline in nontuberculous mycobacteria infections: a retrospective, multicenter cohort of real-world health outcomes
Ghali, Amer El , Alosaimy, Sara , Lucas, Kristen , Tupayachi-Ortiz, Maria G., Vemula, Raaga, Wadle, Carly , Hamad, Yasir , Zeuli, John D. , Fiske, Christina T. , Simonyan, Anahit, Cimino, Christo , Mammadova, Mehriban, Umana, Virginia, Butt, Saira , Molina, Kyle C. , Thomas, Michael A. , Kaip, Emily A, Gore, Tristan, Howard, Catessa, Cabanilla, M. Gabriela , Frens, Jeremy J , Barger, Melissa, Ong, Aaron, Rybak, Michael J. , El Ghali, Amer , Webb, Andrew J, Rybak, Michael J , Morrisette, Taylor , Philley, Julie V. , Mejía-Chew, Carlos , Stevens, Ryan W. , Webb, Andrew , Hasbun, Rodrigo , Bouchard, Jeannette L. , Holger, Dana J. , Cohen, Keira A.

Mayo Clinic

Antimicrobial Agents and Chemotherapy | September 28, 2023 | Volume: 67 | Issue: 10 | Pages: No page available

10.1128/aac.00824-23 | PMID 37768312 Get It

ABSTRACT Infections due to nontuberculous mycobacteria (NTM) continue to increase in prevalence, leading to problematic clinical outcomes. Omadacycline (OMC) is an aminomethylcycline antibiotic with FDA orphan drug and fast-track designations for pulmonary NTM infections, including Mycobacteroides abscessus (MAB). This multicenter retrospective study across 16 U.S. medical institutions from January 2020 to March 2023 examined the long-term clinical success, safety, and tolerability of OMC for NTM infections. The cohort included patients aged ≥18 yr, who were clinically evaluable, and` had been treated with OMC for ≥3 mo without a previous diagnosis of cystic fibrosis. The primary outcome was 3 mo clinical success, with secondary outcomes including clinical improvement and mortality at 6- and 12 mo, persistence or reemergence of infection, adverse effects, and reasons for OMC utilization. Seventy-five patients were included in this analysis. Most patients were female (48/75, 64.0%) or Caucasian (58/75, 77.3%), with a median (IQR) age of 59 yr (49–67). Most had NTM pulmonary disease (33/75, 44.0%), skin and soft tissue disease (19/75, 25.3%), or osteomyelitis (10/75, 13.3%), and Mycobacterium abscessus (60/75, 80%) was the most commonly isolated NTM pathogen. The median (IQR) treatment duration was 6 mo ( 4 – 14 ), and the most commonly co-administered antibiotic was azithromycin (33/70, 47.1%). Three-month clinical success was observed in 80.0% (60/75) of patients, and AEs attributable to OMC occurred in 32.0% (24/75) of patients, leading to drug discontinuation in 9.3% (7/75).
Acute and Longer-Term Effects of COVID-19 on Auditory and Vestibular Symptoms
Berlot, Ashley , Moskowitz, Howard S. , Lin, Juan , Liu, Jianyou, Sehanobish, Esha , Jerschow, Elina , Ow, Thomas J. , Sussman, Elyse

Mayo Clinic

Otology & Neurotology | September 27, 2023 | Volume: 44 | Issue: 10 | Pages: 1100-1105

10.1097/mao.0000000000004027 | PMID 37758317 Get It

Objective To evaluate long-term effects of COVID-19 on auditory and vestibular symptoms in a diverse cohort impacted by the initial 2020 COVID-19 infection in the pandemic's epicenter, before vaccine availability. Study Design Cohort study of individuals with confirmed COVID-19 infection, diagnosed in the March–May 2020 infection wave. A randomized, retrospective chart review of 1,352 individuals was performed to identify those with documented new or worsening auditory (aural fullness, tinnitus, hyperacusis, hearing loss) or vestibular (dizziness, vertigo) symptoms. Those with documented symptoms (613 of the 1,352 initial cohort) were contacted for a follow-up telephone survey in 2021–2022 to obtain self-report of aforementioned symptoms. Setting Academic tertiary hospital system in Bronx, NY. Patients Adults 18 to 99 years old with confirmed COVID-19 infection, alive at time of review. One hundred forty-eight charts were excluded for restricted access, incomplete data, no COVID-19 swab, or deceased at time of review. Intervention Confirmed COVID-19 infection, March to May 2020. Main Outcomes Measures Auditory and vestibular symptoms documented in 2020 medical records and by self-report on 2021 to 2022 survey. Results Among the 74 individuals with documented symptoms during the first 2020 COVID-19 wave who participated in the 2021 to 2022 follow-up survey, 58% had documented vestibular symptoms initially in 2020, whereas 43% reported vestibular symptoms on the 2021 to 2022 survey (p = 0.10). In contrast, 9% had documented auditory symptoms initially in 2020 and 55% reported auditory symptoms on the 2021 to 2022 survey (p < 0.01). Conclusions COVID-19 may impact vestibular symptoms early and persistently, whereas auditory effects may have more pronounced long-term impact, suggesting the importance of continually assessing COVID-19 patients.
Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization
Rahman, Rifaquat , Trippa, Lorenzo , Lee, Eudocia Q. , Arrillaga‐Romany, Isabel , Fell, Geoffrey, McCluskey, Christine , Wiley, Jennifer, Gaffey, Sarah, Welch, Mary , Ahluwalia, Manmeet S. , Colman, Howard , Hepel, Jaroslaw T., Elinzano, Heinrich, Schiff, David , Chukwueke, Ugonma , Beroukhim, Rameen , Nayak, Lakshmi , Batchelor, Tracy T. , Rinne, Mikael L. , Lu‐Emerson, Christine , Mellinghoff, Ingo K. , Haas‐Kogan, Daphne A. , Tanguturi, Shyam , Cagney, Daniel , Aizer, Ayal A. , Doherty, Lisa, Lavallee, Maria, Fisher-Longden, Brittany, Dowling, Shanna, Geduldig, Jack , Watkinson, Fiona , Pisano, William , Ramkissoon, Shakti, Reardon, David A. , Wen, Patrick Y. , Touat, Mehdi , Welch, Mary R , Ahluwalia, Manmeet S , Colman, Howard , Nabors, Louis Burt , Chukwueke, Ugonma N , Nayak, Lakshmi , Batchelor, Tracy T , Kaley, Thomas , Lu-Emerson, Christine , Mellinghoff, Ingo K , Bi, Wenya Linda , Peruzzi, Pier Paolo , Haas-Kogan, Daphne , Aizer, Ayal , Geduldig, Jack , Pisano, William , Chiocca, E Antonio , Reardon, David A , Alexander, Brian M , Ligon, Keith L , Wen, Patrick Yung , Tanguturi, Shyam K , Arrillaga‐Romany, Isabel , Fell, Geoffrey G. , Drappatz, Jan , Galanis, Evanthia , Nabors, Burt , McFaline-Figueroa, J Ricardo , Arnaout, Omar M. , Malinowski, Seth W. , Santagata, Sandro , Meredith, David M. , Alexander, Brian M.

Mayo Clinic

Journal of Clinical Oncology | September 18, 2023 | Volume: 41 | Issue: 36 | Pages: 5524-5535

10.1200/jco.23.00493 | PMID 37722087 Get It

PURPOSE The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) is a phase II platform trial that uses response adaptive randomization and genomic profiling to efficiently identify novel therapies for phase III testing. Three initial experimental arms (abemaciclib [a cyclin-dependent kinase [CDK]4/6 inhibitor], neratinib [an epidermal growth factor receptor [EGFR]/human epidermal growth factor receptor 2 inhibitor], and CC-115 [a deoxyribonucleic acid–dependent protein kinase/mammalian target of rapamycin inhibitor]) were simultaneously evaluated against a common control arm. We report the results for each arm and examine the feasibility and conduct of the adaptive platform design. PATIENTS AND METHODS Patients with newly diagnosed O 6 -methylguanine–DNA methyltransferase-unmethylated glioblastoma were eligible if they had tumor genotyping to identify prespecified biomarker subpopulations of dominant glioblastoma signaling pathways (EGFR, phosphatidylinositol 3-kinase, and CDK). Initial random assignment was 1:1:1:1 between control (radiation therapy and temozolomide) and the experimental arms. Subsequent Bayesian adaptive randomization was incorporated on the basis of biomarker-specific progression-free survival (PFS) data. The primary end point was overall survival (OS), and one-sided P values are reported. The trial is registered with ClinicalTrials.gov (identifier: NCT02977780 ). RESULTS Two hundred thirty-seven patients were treated (71 control; 73 abemaciclib; 81 neratinib; 12 CC-115) in years 2017-2021. Abemaciclib and neratinib were well tolerated, but CC-115 was associated with ≥ grade 3 treatment-related toxicity in 58% of patients. PFS was significantly longer with abemaciclib (hazard ratio [HR], 0.72; 95% CI, 0.49 to 1.06; one-sided P = .046) and neratinib (HR, 0.72; 95% CI, 0.50 to 1.02; one-sided P = .033) relative to the control arm but there was no PFS benefit with CC-115 (one-sided P = .523). None of the experimental therapies demonstrated a significant OS benefit ( P > .05). CONCLUSION The INSIGhT design enabled efficient simultaneous testing of three experimental agents using a shared control arm and adaptive randomization. Two investigational arms had superior PFS compared with the control arm, but none demonstrated an OS benefit. The INSIGhT design may promote improved and more efficient therapeutic discovery in glioblastoma. New arms have been added to the trial.
SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers.
Shroff, Rachna T. , Guthrie, Katherine A. , Scott, Aaron J. , Goff, Laura W. , Matin, Khalid , Kalyan, Aparna, Javle, Milind , Aghajanian, Carol , Tan, Benjamin , Cheema, P. , Iyer, Renuka , Kelley, Robin Kate , Thumar, Jaykumar , Chiorean, E. Gabriela , Höchster, Howard S. , Philip, Philip Agop, Borad, Mitesh J. , Mahipal, Amit , Patel, Anuj , El-Khoueiry, Anthony B.

Mayo Clinic

Journal of Clinical Oncology | September 14, 2023 | Volume: 41 | Issue: 4_suppl | Pages: No page available

10.1200/jco.2023.41.4_suppl.lba490 Get It

LBA490 Background: Biliary tract cancers (BTCs) are a heterogeneous group of malignancies with a dismal prognosis. Gemcitabine-based regimens are the standard of care in advanced disease, but median overall survival (OS) is roughly 12 months. The addition of albumin-bound paclitaxel to gemcitabine and cisplatin (GAP) demonstrated promising efficacy in a 60 patient, single-arm phase II study (Shroff et al, JAMA Oncol 2019), with observed median OS of 19.2 months. Methods: SWOG 1815 is a randomized, open-label, phase III trial comparing GAP to gemcitabine/cisplatin (GC). The study included newly diagnosed advanced BTC patients (pts), randomized 2:1 to GAP vs. GC. GAP included gemcitabine at 800 mg/m2, cisplatin at 25 mg/m2 and albumin-bound paclitaxel at 100 mg/m2 on days 1 and 8 of a 21-day cycle. GC included standard dosing of gemcitabine at 1000 mg/m2 and cisplatin at 25 mg/m2 on days 1 and 8 of a 21-day cycle. Pts were treated until progression. The primary endpoint was overall survival (OS) with a target hazard ratio of 0.7 with 90% power and a 1-sided alpha of 0.025; randomization was stratified by disease site (intrahepatic cholangiocarcinoma [CCA] vs gallbladder adenocarcinoma [GBC] vs extrahepatic CCA), disease stage (locally advanced vs metastatic), and Zubrod PS 0 vs 1. Results: Of 441 eligible pts randomized, 55% were female. 67% of patients had intrahepatic CCA, 16% had GBC and 17% had extrahepatic CCA. Most pts had metastases (73%). Median OS with GAP vs. GC was 14 vs. 12.7 mo respectively (HR 0.93, 95% CI 0.74-1.19, p=0.58), ORR (confirmed and unconfirmed) 34% vs 25% (p=0.11) and median PFS 8.2 vs 6.4 mo (HR 0.92, 95% CI 0.72-1.16, p=0.47), respectively. Grade 3 and 4 treatment related adverse events (TRAEs) in ≥10% of pts for GAP and GC were anemia, neutropenia, and thrombocytopenia. GAP had more ≥ grade 3 hematologic AEs compared to the GC arm (60% vs. 45%, p=0.003). Discontinuation due to toxicity was at 24% vs 19% (p=0.26) with GAP vs GC. In exploratory subset analyses, GAP vs GC improved OS in pts with locally advanced disease (medians 19.2 vs 13.7 mo; HR 0.67, 95% CI 0.42-1.06, p=0.09) and in GBC pts (medians 17.0 vs 9.3 mo; HR 0.74, 95% CI 0.41-1.35, p=0.33). ORR for GAP vs GC in GBC was 50% vs 24% (p=0.09) and for locally advanced disease 28 vs 21% p=0.74. Conclusions: SWOG 1815 did not result in a statistically significant improvement in median OS with GAP vs. GC. The GAP regimen had higher rates of TRAEs without a statistically significant difference in discontinuation rates. Pts with locally advanced disease and GBC may benefit from the use of GAP. Further analyses are ongoing to understand potential benefit of GAP in subsets of BTC pts. Funding: NIH/National Cancer Institute grants CA180888, CA180819, CA180820, CA180821, and CA180868; and in part by Celgene Corporation, Summit, NJ (subsidiary of Bristol Myer Squibb). Clinical trial information: NCT#03768414 .
CYP2D6 ‐guided opioid therapy for adults with cancer pain: A randomized implementation clinical trial
Mosley, Scott A. , Cicali, Emily J. , Cueto, Alex Del, Portman, Diane , Donovan, Kristine A. , Gong, Yan , Langaee, Taimour , Gopalan, Priya, Schmit, Jessica M., Starr, Jason S. , Silver, Natalie L. , Chang, Young D. , Rajasekhara, Sahana , Smith, Joshua E., Clare‐Salzler, Michael , Starostik, Petr , McLeod, Howard L. , Hicks, J. Kevin , Cicali, Emily , George, Thomas J , Hicks, J Kevin , Cavallari, Larisa H , Soares, Heloisa P. , George, Thomas J. , Fillingim, Roger Benton , Cavallari, Larisa H.

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | September 12, 2023 | Volume: 43 | Issue: 12 | Pages: 1286-1296

10.1002/phar.2875 | PMID 37698371 Get It

Abstract Introduction The CYP2D6 enzyme metabolizes opioids commonly prescribed for cancer‐related pain, and CYP2D6 polymorphisms may contribute to variability in opioid response. We evaluated the feasibility of implementing CYP2D6 ‐guided opioid prescribing for patients with cancer and reported pilot outcome data. Methods Adult patients from two cancer centers were prospectively enrolled into a hybrid implementation‐effectiveness clinical trial and randomized to CYP2D6 ‐genotype‐guided opioid selection, with clinical recommendations, or usual care. Implementation metrics, including provider response, medication changes consistent with recommendations, and patient‐reported pain and symptom scores at baseline and up to 8 weeks, were assessed. Results Most (87/114, 76%) patients approached for the study agreed to participate. Of 85 patients randomized, 71% were prescribed oxycodone at baseline. The median (range) time to receive CYP2D6 test results was 10 (3–37) days; 24% of patients had physicians acknowledge genotype results in a clinic note. Among patients with CYP2D6 ‐genotype‐guided recommendations to change therapy ( n = 11), 18% had a change congruent with recommendations. Among patients who completed baseline and follow‐up questionnaires ( n = 48), there was no difference in change in mean composite pain score (−1.01 ± 2.1 vs. −0.41 ± 2.5; p = 0.19) or symptom severity at last follow‐up (3.96 ± 2.18 vs. 3.47 ± 1.78; p = 0.63) between the usual care arm ( n = 26) and genotype‐guided arm ( n = 22), respectively. Conclusion Our study revealed high acceptance of pharmacogenetic testing as part of a clinical trial among patients with cancer pain. However, provider response to genotype‐guided recommendations was low, impacting assessment of pain‐related outcomes. Addressing barriers to utility of pharmacogenetics results and clinical recommendations will be critical for implementation success.
Colorectal Signet Ring Cell Carcinoma Presenting as Ulcerating Rectosigmoid Stricture
Chen, Bing , Liu, Bolun , Sun, Katherine , Chung, Howard , Zheng, Beishi, Cordeiro, Christopher, Virmani, Chetan, Shapsis, Alexander, Liu, Bolun , Yuan, Zhiming

Mayo Clinic

ACG Case Reports Journal | August 17, 2023 | Volume: 10 | Issue: 8 | Pages: e01130

10.14309/crj.0000000000001130 | PMID 37601300 Get It

ABSTRACT Colorectal signet ring cell carcinoma is a rare type of colon cancer. Early diagnosis remains challenging because of nonspecific colonoscopy findings, such as diffuse circumferential thickening, stricture, and ulcerations, and the potential absence of typical pathological features in the initial biopsy sample. In this article, we report a 41-year-old man with ulcerating rectosigmoid stricture in the rectosigmoid colon with inconclusive histology. Subsequently, the patient developed small bowel obstruction and was diagnosed with stage 4 colorectal signet ring cell carcinoma with peritoneal carcinomatosis.